CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amarantus Bioscience Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amarantus Bioscience Holdings Inc
655 Montgomery Street, Suite 900
Phone: (408) 737-2734p:408 737-2734 SAN FRANCISCO, CA  94111  United States Ticker: AMBSAMBS

This company ceased filing statements with the SEC on 12/4/2017.

Business Summary
Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201612/31/2015YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director Gerald E.Commissiong 33 10/23/2011 4/1/2011
Chief Financial Officer, Interim Chief Operating Officer BarneyMonte 4/5/2018 4/5/2018
Chief Scientific Officer, Director John W.Commissiong 71 1/1/2008 1/1/2008
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
DioGenix, Inc. 50 West Watkins Mill Road Gaithersburg MD United States

Business Names
Business Name
Amarantus Diagnostics Inc.
Amarantus MA, Inc.
Amarantus Therapeutics, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 10 (As of 12/31/2014)
Outstanding Shares: 630,607,411 (As of 3/31/2023)
Shareholders: 82
Stock Exchange: OTC
Federal Tax Id: 260690857
Fax Number: (408) 852-4427


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023